TELA Bio, Inc. (TELA) stock
TELANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$0.69−0.04 (-5.27%)
Close on Nov 20, 2026Market cap $30.91MP/E –Yield –
TELA Bio revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
TELA Bio's revenue for the twelve months ending Jun 30, 2026 was $79.91M, up 6.1% year over year. For fiscal 2025 it was $80.28M, up 15.8% from the year before. The highest annual figure on record is $80.28M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $80.28M | +15.8% |
| FY2024 | Dec 31, 2024 | $69.30M | +18.6% |
| FY2023 | Dec 31, 2023 | $58.45M | +41.1% |
| FY2022 | Dec 31, 2022 | $41.42M | +40.6% |
| FY2021 | Dec 31, 2021 | $29.46M | +61.8% |
| FY2020 | Dec 31, 2020 | $18.21M | +17.9% |
| FY2019 | Dec 31, 2019 | $15.45M | +86.7% |
| FY2018 | Dec 31, 2018 | $8.27M | +94.9% |
| FY2017 | Dec 31, 2017 | $4.25M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $19.29M | -4.5% |
| Q1 FY2026 | Mar 31, 2026 | $19.06M | +2.9% |
| Q4 FY2025 | Dec 31, 2025 | $20.87M | +18.2% |
| Q3 FY2025 | Sep 30, 2025 | $20.69M | +9.1% |
| Q2 FY2025 | Jun 30, 2025 | $20.20M | +25.5% |
| Q1 FY2025 | Mar 31, 2025 | $18.52M | +11.5% |
| Q4 FY2024 | Dec 31, 2024 | $17.65M | +3.8% |
| Q3 FY2024 | Sep 30, 2024 | $18.96M | +25.9% |
| Q2 FY2024 | Jun 30, 2024 | $16.09M | +11.0% |
| Q1 FY2024 | Mar 31, 2024 | $16.60M | +39.4% |
| Q4 FY2023 | Dec 31, 2023 | $17.00M | +46.3% |
| Q3 FY2023 | Sep 30, 2023 | $15.05M | +34.9% |
| Q2 FY2023 | Jun 30, 2023 | $14.49M | +39.3% |
| Q1 FY2023 | Mar 31, 2023 | $11.91M | +44.7% |
| Q4 FY2022 | Dec 31, 2022 | $11.62M | +38.8% |
| Q3 FY2022 | Sep 30, 2022 | $11.16M | +45.8% |
| Q2 FY2022 | Jun 30, 2022 | $10.41M | +37.7% |
| Q1 FY2022 | Mar 31, 2022 | $8.23M | +40.1% |
| Q4 FY2021 | Dec 31, 2021 | $8.37M | +47.8% |
| Q3 FY2021 | Sep 30, 2021 | $7.65M | +44.1% |
| Q2 FY2021 | Jun 30, 2021 | $7.56M | +115.5% |
| Q1 FY2021 | Mar 31, 2021 | $5.88M | +57.7% |
| Q4 FY2020 | Dec 31, 2020 | $5.67M | +71.6% |
| Q3 FY2020 | Sep 30, 2020 | $5.31M | +60.7% |
| Q2 FY2020 | Jun 30, 2020 | $3.51M | +44.5% |
| Q1 FY2020 | Mar 31, 2020 | $3.73M | +68.4% |
| Q2 FY2019 | Jun 30, 2019 | $3.30M | – |
| Q1 FY2019 | Mar 31, 2019 | $3.31M | – |
| Q4 FY2018 | Dec 31, 2018 | $2.43M | – |
| Q3 FY2018 | Sep 30, 2018 | $2.21M | – |
See a number that looks wrong?